News
-
-
REGULATED PRESS RELEASE
BIOPHYTIS REPORTS ITS PROVISIONAL FINANCIAL RESULTS AND PROVIDES ITS STRATEGIC OUTLOOK
Biophytis reports provisional financial results for fiscal year 2025 and strategic outlook, including milestones in sarcopenia and obesity programs, engagement with scientific community, and financial restructuring -
-
-
-
-
-
-
-
PRESS RELEASE
BIOPHYTIS STRATEGIC UPDATE: JOINT VENTURE REGISTRATION FILING SUBMITTED IN HONG KONG
Biophytis submits registration filing for joint venture in Hong Kong with Asian partners, including Ronghui Renhe Life Technology, aiming to advance BIO101 development in sarcopenia across Asian markets